The STCC was set up in November 2019 under the Research, Innovation and Enterprise (RIE) 2020 funding as a nationally coordinated, virtual organisation to address the need for a cohesive and collaborative national level cancer Research & Translation (R&T) platform. It aims to synergise cancer research capabilities, and raise Singapore’s overall prominence, competitiveness and healthcare impact regionally and globally in selected cancers. It was registered as a business unit under the Consortium for Clinical Research and Innovation, Singapore (CRIS) in April 2020.
In STCC Phase 1, the foundational framework for a national level R&T programme comprising four joint platforms was established to bring together top basic, clinical and translational talent and expertise in the cancer research ecosystem. A central coordinating office (Strategic Planning and Development office) was also set up to manage daily operations and resource management, drive and track deliverables, and support the STCC leadership in running the consortium.
STCC Phase 2 will be a continued effort from Phase 1 to further develop and augment the cancer R&T infrastructure, and drive cohesiveness in the research community. STCC aims to:
STCC Phase 2 will follow these key operating principles:
Cancer Clinical Trials & Investigational Medicine Units
Cancer Databases & Tissue Banks
Translational Research Integration & Support
Business Intelligence & Development